{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"A&#160;Retrospective, Multicountry Study of Clinical Outcomes in Patients with Relapsed/ Refractory Multiple Myeloma Treated with T-cell Redirectors Outside of Clinical Trials (REALiTEC)<br /><div>\n  64007957MMY4004\n  [REALiTEC]</div>","eudractNumber":null,"id":8882,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06285318","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-05-01T10:04:17+02:00","shortTitle":"REALiTEC","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Effekt einer zus&#228;tzlichen Braun-Fu&#223;punkt-Anastomose bei Patienten nach Pankreaskopfresektion<div>DFG&#160;- Projektnummer 416055422<br /></div><div><br /></div>","eudractNumber":null,"id":7837,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2022-07-28T12:12:42+02:00","shortTitle":"RECOPS","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A PHASE 2 AND PHASE 3 PERI-OPERATIVE TRIAL OF FIANLIMAB AND \nCEMIPLIMAB COMPARED WITH ANTI-PD1 ALONE IN PATIENTS WITH \nRESECTABLE STAGE III AND IV MELANOMA","eudractNumber":"2022-502825-17-00","id":9882,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[{"name":"LAG-3","id":"mt_39"}],"nctNumber":"NCT06190951","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2025-10-09T09:45:47+02:00","shortTitle":"REGENERON / R3767-ONC-2208","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"},{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"A Phase I Trial to Determine the Maximum Tolerated Dose and Patient-specific Dosimetry of Fractionated Intracavitary Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment","eudractNumber":null,"id":9750,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"}],"mutations":[],"nctNumber":"NCT05533242","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2023-10-24T09:40:15+02:00","shortTitle":"RIT in GBM (NOA-22)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Registerplattform H&#228;matologische Neoplasien (RUBIN) - Erweiterung des Tumorregisters Lymphatische Neoplasien","eudractNumber":null,"id":10683,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06043011","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-10-23T08:42:46+02:00","shortTitle":"RUBIN","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Randomized multi-centre open-label non-inferiority phase 3 clinical trial for patients with a stage IV childhood renal tumor comparing upfront Vincristine, Actinomycin-D and Doxorubicin (VAD, standard arm) with upfront Vincristine, Carboplatin and Etoposide (VCE, experimental arm)<br />","eudractNumber":"2023-508926-91-00","id":4077,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT03669783","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-03-30T09:41:03+02:00","shortTitle":"Randomet2017","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"","eudractNumber":null,"id":11211,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":null,"shortTitle":"ReBaVeCo","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospective study with continuous and fixed-Duration Ibrutinib based First Line Treatment in patients with Chronic Lymphocytic Leukemnia in real world setting","eudractNumber":null,"id":9253,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-03-03T13:01:22+01:00","shortTitle":"Reality 2","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Simultan integrierter Boost in der HNO Quality Control Registry","eudractNumber":null,"id":2554,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"}],"mutations":[],"nctNumber":"NCT06831903","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2019-10-01T13:24:30+02:00","shortTitle":"Register SIB HNO","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Patientenregister Seltene Histiocytosen","eudractNumber":null,"id":10623,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2016-01-01T10:45:51+01:00","shortTitle":"Register für Seltene Histiocytosen","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}